Literature DB >> 33473247

Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies.

Susanna Asseyer1,2, Graham Cooper1,2,3, Friedemann Paul1,2,3,4.   

Abstract

Neuromyelitis optica spectrum disorders (NMOSDs) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) are autoimmune inflammatory disorders of the central nervous system (CNS). Pain is highly prevalent and debilitating in NMOSD and MOGAD with a severe impact on quality of life, and there is a critical need for further studies to successfully treat and manage pain in these rare disorders. In NMOSD, pain has a prevalence of over 80%, and pain syndromes include neuropathic, nociceptive, and mixed pain, which can emerge in acute relapse or become chronic during the disease course. The impact of pain in MOGAD has only recently received increased attention, with an estimated prevalence of over 70%. These patients typically experience not only severe headache, retrobulbar pain, and/or pain on eye movement in optic neuritis but also neuropathic and nociceptive pain. Given the high relevance of pain in MOGAD and NMOSD, this article provides a systematic review of the current literature pertaining to pain in both disorders, focusing on the etiology of their respective pain syndromes and their pathophysiological background. Acknowledging the challenge and complexity of diagnosing pain, we also provide a mechanism-based classification of NMOSD- and MOGAD-related pain syndromes and summarize current treatment strategies.
Copyright © 2020 Asseyer, Cooper and Paul.

Entities:  

Keywords:  aquaporin 4; headache; myelin oligodendrocyte glycoprotein-antibody-associated disease; neuromyelitis optica spectrum disorders; neuropathic pain; pain; painful tonic spasms

Year:  2020        PMID: 33473247      PMCID: PMC7812141          DOI: 10.3389/fneur.2020.00778

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  6 in total

Review 1.  [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification].

Authors:  Orhan Aktas; Tania Kümpfel
Journal:  Nervenarzt       Date:  2021-03-16       Impact factor: 1.214

2.  Differences in Neuropathic Pain and Radiological Features Between AQP4-ON, MOG-ON, and IDON.

Authors:  Hao Kang; Huaiyu Qiu; Xiaofeng Hu; Shihui Wei; Yong Tao
Journal:  Front Pain Res (Lausanne)       Date:  2022-05-09

Review 3.  Pain in Multiple Sclerosis: Understanding Pathophysiology, Diagnosis, and Management Through Clinical Vignettes.

Authors:  Michael K Racke; Elliot M Frohman; Teresa Frohman
Journal:  Front Neurol       Date:  2022-01-13       Impact factor: 4.003

Review 4.  Interleukin-6: evolving role in the management of neuropathic pain in neuroimmunological disorders.

Authors:  Kenichi Serizawa; Haruna Tomizawa-Shinohara; Shota Miyake; Kenji Yogo; Yoshihiro Matsumoto
Journal:  Inflamm Regen       Date:  2021-11-02

Review 5.  Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.

Authors:  Tina Nie; Hannah A Blair
Journal:  CNS Drugs       Date:  2022-09-07       Impact factor: 6.497

Review 6.  Clinical and neuroimaging findings in MOGAD-MRI and OCT.

Authors:  Frederik Bartels; Angelo Lu; Frederike Cosima Oertel; Carsten Finke; Friedemann Paul; Claudia Chien
Journal:  Clin Exp Immunol       Date:  2021-07-18       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.